DATROWAY
LaunchADCBLAINJECTIONINJECTABLEPriority Review
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
DATROWAY by Daiichi Sankyo is deruxtecan-dlnk, is a trop-2-directed antibody-drug conjugate. Approved for metastatic epidermal growth factor receptor (egfr)-mutated non-small cell lung cancer (nsclc), platinum-based chemotherapy, metastatic and 6 more indications. First approved in 2025.
Drug data last refreshed Yesterday
Mechanism of Action
deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to Trop-2 on cells, including tumor cells, datopotamab…
Worked on DATROWAY at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.